Starna Therapeutics recently announced the completion of a Series B+ financing round raising nearly $40 million. This round saw participation from a prominent industry fund alongside Hillhouse Ventures, LYFE Capital, Lilly Asia Ventures (LAV), Sherpa Healthcare Partners, Source Code Capital, and Primavera Capital.

Following a $44 million Series B financing round, the company has once again secured backing from prominent institutions after a six-month interval. The proceeds will be primarily used to accelerate the clinical development of multiple in vivo cell therapy (in vivo CAR-T) pipelines, advance the establishment of extra-hepatic delivery platforms—targeting the lungs, intestines, and nervous system—and further strengthen the company’s innovative R&D footprint in the field of mRNA therapeutics.

Starna Therapeutics is a clinical-stage company focused on mRNA drug development, dedicated to creating innovative mRNA therapies for patients worldwide through its proprietary extra-hepatic delivery technology. The company has established a robust pipeline spanning prophylactic infectious disease vaccines, therapeutic cancer vaccines, protein replacement therapies, and in vivo cell therapies. For more information, please visit www.starnatx.com.